Mexico Greenlights CURE Pharmaceutical's Drug Delivery Innovation Through Milagro Pharmaceuticals Partnership

CURE Pharmaceutical has achieved a major regulatory milestone as Mexico’s COFEPRIS authority (the country’s equivalent to the FDA) approved manufacturing and distribution rights for the company’s patented oral thin film products. This authorization marks a significant expansion into the Latin American market through a strategic partnership with Milagro Pharmaceuticals.

The Product Portfolio Entering the Mexican Market

The approved portfolio spans multiple therapeutic and wellness categories, leveraging CURE Pharmaceutical’s proprietary CUREform™ delivery platform:

CUREfilm Blue™ represents a sildenafil citrate formulation designed to address erectile dysfunction, offering a convenient oral thin film alternative to traditional tablets. The product joins a comprehensive wellness lineup entering Mexico.

Additional approved products include a weekly Vitamin D3 supplement (40,000 IU dosing), a sugar-free electrolyte energy product, and a melatonin-based sleep support formula. Each utilizes the company’s innovative oral thin film technology that dissolves on the tongue, eliminating the need for water or food.

Strategic Market Entry Through Milagro Pharmaceuticals

Milagro Pharmaceuticals, which has demonstrated rapid expansion across multiple markets including Colombia and Canada, will spearhead the Mexican and broader Latin American distribution strategy. Martin Simon, leading Milagro Pharmaceuticals as CEO, emphasized the collaboration’s potential: “The partnership with CURE enables us to bring proprietary wellness solutions and advanced delivery mechanisms to Mexico with plans to scale across the entire Latin American region, where demand for health and wellness innovations continues accelerating.”

CURE Pharmaceutical is currently engaged with multiple large-scale distributors throughout Mexico and the Latin American region to establish comprehensive market coverage.

Manufacturing and Market Readiness

The company’s 25,000 square-foot manufacturing facility, FDA and DEA registered with NSF® cGMP certification, now serves as the production hub for these Mexican-market products. This vertically integrated capability positions CURE Pharmaceutical to rapidly scale production while maintaining regulatory compliance and quality standards.

The Mexican market entry is projected to accelerate production ramp-up at the facility where the CUREform™ platform was originally developed and pioneered. Management expects to finalize distribution partnerships across the LATAM territory within the coming months, creating momentum for broader regional expansion.

This regulatory approval represents validation of CURE Pharmaceutical’s oral thin film technology and opens significant revenue opportunities in markets where demand for innovative wellness delivery systems remains largely underserved.